Amgen Reports Results of Repatha (evolocumab) in P-III (FOURIER) OLE Studies for the Treatment of Atherosclerotic Cardiovascular Disease
Shots:
- The 2 P-III (FOURIER) OLE studies are composed of (20130295) & (20160250) evaluating Repatha (140mg, q2w/420mg, qm) in 5035 patients in eastern EU & US & 1600 patients in western EU with atherosclerotic CVD
- The results showed that the therapy was found to be safe & well-tolerated. In the OLE studies, patients received Repatha for ~5 &~8.5yrs. with no new safety results. The therapy also showed a sustained reduction in LDL-C levels with ≥85% achieved an LDL-C level of <40 mg/dL during the OLE period
- Additionally, other study measures included exploratory analyses of non-high-density lipoprotein cholesterol & multiple other measures. Repatha is being studied in an ongoing (VESALIUS-CV) trial
Ref: PRNewswire| Image: Amgen
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
